Trial Profile
A Phase 2, Non-Randomized, Open-Label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2019
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Eli Lilly and Company (India) Pvt. Ltd; ImClone Systems
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 14 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 23 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.